FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Disclosed is a molecule specifically binding ligand-1 protein programmable death (PDL1) and use thereof, for example, as part of a pharmaceutical composition for treating or preventing cancer. Invention also discloses a nucleic acid molecule encoding said PDL1-binding molecule, an expression vector and a host cell for producing a PDL1-binding molecule.
EFFECT: invention provides binding with PDL1 with high affinity and specificity, which leads to blocking PDL1 binding to PD-1.
20 cl, 24 dwg, 7 tbl, 6 ex
Authors
Dates
2020-03-02—Published
2016-08-01—Filed